US Stock Insider Trading | Syndax discloses 2 insider transactions on February 10

K-LinePoet · 2026-02-20T22:20:49+00:00

Syndax Pharmaceuticals disclosed insider trading activities on February 10, 2026. Director Metzger Michael A sold 17,200 shares on February 9, totaling $360,800. Executive Goldan Keith A also made multiple transactions, buying and selling stocks involving significant amounts. The company focuses on developing cancer therapies and is working on a new small-molecule inhibitor, revumenib.

K-LinePoet

2026-02-20 22:20:49

Abstract generation in progress

On February 10, 2026, Syndax (SNDX) disclosed two insider trading transactions. Director Metzger Michael A sold 17,200 shares on February 9, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 10, 2026	Director	Metzger Michael A	February 9, 2026	Sell	17,200	21.03	360,800
February 10, 2026	Executive	Goldan Keith A.	February 9, 2026	Sell	3,410	21.03	71,700
February 6, 2026	Executive	Goldan Keith A.	January 30, 2026	Buy	1,219	8.48	10,300
February 6, 2026	Executive	Goldan Keith A.	February 6, 2026	Sell	2,082	20.62	42,900
February 6, 2026	Director	Metzger Michael A	February 6, 2026	Sell	7,412	20.62	152,800
September 8, 2025	Director	Metzger Michael A	September 8, 2025	Sell	157,300	16.41	2,582,000
September 8, 2025	Director	Metzger Michael A	September 8, 2025	Buy	157,300	10.90	1,714,600
August 18, 2025	Director	Podlesak Dennis	August 18, 2025	Buy	57,600	7.20	414,700
August 18, 2025	Director	Podlesak Dennis	August 18, 2025	Sell	19,200	15.84	304,200
August 14, 2025	Director	Podlesak Dennis	August 14, 2025	Sell	19,200	14.19	272,500

[Company Profile]

Syndax Pharmaceuticals, Inc. was incorporated on October 11, 2005, under the laws of Delaware. The company is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The company is developing revumenib, a potent, selective small-molecule inhibitor of menin-MLL interaction, for the treatment of KMT2A rearranged or KMT2A-r, also known as mixed lineage leukemia rearrangement or MLLr, including acute lymphoblastic leukemia (ALL), acute leukemia, acute myeloid leukemia (AML), and NPM1-mutated AML.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes